Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.

Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21.

PMID:
18182081
2.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group..

J Clin Oncol. 2009 Aug 20;27(24):3994-4001. doi: 10.1200/JCO.2008.21.1128. Epub 2009 Jul 13.

PMID:
19597025
3.

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA.

Leuk Lymphoma. 2009 Oct;50(10):1589-96.

PMID:
19863336
4.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.

J Clin Oncol. 2006 May 20;24(15):2337-42. Epub 2006 Apr 17.

PMID:
16618945
5.

Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.

Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.

Haematologica. 2007 Oct;92(10):1367-74.

6.

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.

Bezares RF, Stemelin G, Diaz A, Argentieri D, Zubiaur EL, Garay G, Bartomioli M, Ryser R, Milone G.

Leuk Lymphoma. 2011 Oct;52(10):1936-41. doi: 10.3109/10428194.2011.584991. Epub 2011 Jun 30.

PMID:
21718136
7.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR.

Blood. 2002 May 15;99(10):3554-61.

8.

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Elter T, Kilp J, Borchmann P, Schulz H, Hallek M, Engert A.

Haematologica. 2009 Jan;94(1):150-2. doi: 10.3324/haematol.13379. Epub 2008 Nov 10. No abstract available.

9.

A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.

Cortelezzi A, Pasquini MC, Sarina B, Bertani G, Grifoni F, Colombi M, Lambertenghi Deliliers G.

Haematologica. 2005 Mar;90(3):410-2.

11.

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.

J Clin Oncol. 2002 Sep 15;20(18):3891-7.

PMID:
12228210
12.

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG.

Leuk Lymphoma. 2007 Oct;48(10):1931-9.

PMID:
17917961
13.

What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?

Byrd JC, Rai KR.

Semin Oncol. 2000 Aug;27(4):xii-xv; discussion xv-xvi. No abstract available.

PMID:
10950363
14.

Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Gritti G, Reda G, Maura F, Piciocchi A, Baldini L, Molica S, Neri A, Cortelezzi A.

Leuk Lymphoma. 2012 Mar;53(3):424-9. doi: 10.3109/10428194.2011.623258. Epub 2012 Jan 5.

PMID:
21919823
15.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.

16.

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia..

Cancer. 2006 Nov 15;107(10):2408-16.

17.

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.

Kiaii S, Choudhury A, Mozaffari F, Rezvany R, Lundin J, Mellstedt H, Osterborg A.

Leuk Lymphoma. 2006 Jul;47(7):1229-38.

PMID:
16923551
18.

Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

Galimberti S, Cervetti G, Cecconi N, Fazzi R, Pacini S, Guerrini F, Manetti C, Caracciolo F, Petrini M.

J Immunother. 2004 Sep-Oct;27(5):389-93.

PMID:
15314547
19.

Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.

Robak T.

Transfus Apher Sci. 2005 Feb;32(1):33-44. Review.

PMID:
15737872
20.

Supplemental Content

Support Center